RecruitingNot ApplicableNCT06462352

Multicenter Study Comparing AI-Based Navicam vs. Conventional Pillcam in Small Bowel Pathology

Multicenter Study Comparing the Artificial Intelligence-Based Navicam Endoscopic Capsule With the Conventional Pillcam Endoscopic Capsule in Small Bowel Pathology


Sponsor

Hospital Clinic of Barcelona

Enrollment

147 participants

Start Date

May 27, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Since its introduction in 2001, small bowel capsule endoscopy has been pivotal in diagnosing small bowel pathology due to its minimally invasive nature and high diagnostic accuracy. However, the technology has limitations, including prolonged reading times and the need for specialized endoscopists. The Navicam endoscopic capsule, leveraging artificial intelligence (AI) with ProScan™ for automated reading, promises to address these limitations by reducing reading times and enhancing diagnostic efficiency. This study aims to assess the diagnostic concordance and to compare the efficiency of the AI-based Navicam capsule with the conventional Pillcam SB3 in the exploration of the small bowel.


Eligibility

Min Age: 18 Years

Inclusion Criteria1

  • Outpatients over 18 years of age with any clinical indication to undergo a small bowel exploration using capsule endoscopy at the participating hospital.

Exclusion Criteria11

  • Patients with known small bowel strictures detected by computed tomography (CT) or magnetic resonance imaging (MRI).
  • Patients with a history of esophagogastric and small bowel surgery (excluding ileocecal resection).
  • Patients with a clinical contraindication for small bowel capsule endoscopy.
  • Hospitalized patients.
  • Patients with pacemaker or Implantable Cardioverter Defibrillator (ICD).
  • Patients scheduled for a MRI within 15 days after capsule endoscopy ingestion.
  • Pregnant or actively breastfeeding patients.
  • Patients with swallowing disorders requiring endoscopic placement of the capsule.
  • Simultaneous participation in another clinical trial using any investigational drug or device.
  • Concurrent life-threatening pathology or condition.
  • Inability to sign the informed consent form.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICENavicam SB capsule

Exploration of the small bowel by Navicam SB endoscopic capsule.

DEVICEPillcam SB3

Exploration of the small bowel by Pillcam SB3 endoscopic capsule.


Locations(16)

Hospital General Universitario Dr Balmis

Alicante, Spain

Hospital Clínic de Barcelona

Barcelona, Spain

Hospital del Mar

Barcelona, Spain

Institut de Recerca Sant Pau (IR-Sant Pau)

Barcelona, Spain

Hospital Universitario de Galdakao

Bilbao, Spain

Hospital General Universitario Virgen la Arrixaca

El Palmar, Spain

Hospital General Universitario de Elche

Elche, Spain

Hospital Clínico San Carlos

Madrid, Spain

Hospital General Universitario Gregorio Marañón

Madrid, Spain

Hospital General Universitario Morales Meseguer

Murcia, Spain

Hospital Universitario Son Espases

Palma de Mallorca, Spain

Hospital Universitario Nuestra Señora de Candelaria

Santa Cruz de Tenerife, Spain

Hospital Universitario Virgen Macarena

Seville, Spain

Hospital de Terrassa

Terrassa, Spain

Hospital General Universitario de Valencia

Valencia, Spain

Hospital Universitario i Politècnic La Fé

Valencia, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06462352